Priveterra Acquisition Corp. Announces Completion Of Business Combination With AEON Biopharma, Inc.
Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/
The resulting combined company changed its name to AEON Biopharma, Inc. and is expected to commence trading of its shares of common stock and warrants on NYSE American LLC ("NYSE") under the ticker symbols "AEON" and "AEON WS," respectively, on July 24, 2023. Mr. Robert Palmisano will join the new 5-member board to serve as a Director.
Mr. Palmisano said, "We are grateful to all investors that continue to support Priveterra's investment thesis in combining with AEON, along with their significant contributions of up to $125 million in arranged funding. I look forward to continuing my journey with AEON as a Director along with its President and CEO, Marc Forth."